Tags

Type your tag names separated by a space and hit enter

Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease.
Molecules. 2020 Mar 11; 25(6)M

Abstract

Alzheimer's disease (AD) is one of the utmost chronic neurodegenerative disorders, which is characterized from a neuropathological point of view by the aggregates of amyloid beta (Aβ) peptides that are deposited as senile plaques and tau proteins which form neurofibrillary tangles (NFTs). Even though advancement has been observed in order to understand AD pathogenesis, currently available therapeutic methods can only deliver modest symptomatic relief. Interestingly, naturally occurring dietary flavonoids have gained substantial attention due to their antioxidative, anti-inflammatory, and anti-amyloidogenic properties as alternative candidates for AD therapy. Experimental proof provides support to the idea that some flavonoids might protect AD by interfering with the production and aggregation of Aβ peptides and/or decreasing the aggregation of tau. Flavonoids have the ability to promote clearance of Aβ peptides and inhibit tau phosphorylation by the mTOR/autophagy signaling pathway. Moreover, due to their cholinesterase inhibitory potential, flavonoids can represent promising symptomatic anti-Alzheimer agents. Several processes have been suggested for the aptitude of flavonoids to slow down the advancement or to avert the onset of Alzheimer's pathogenesis. To enhance cognitive performance and to prevent the onset and progress of AD, the interaction of flavonoids with various signaling pathways is proposed to exert their therapeutic potential. Therefore, this review elaborates on the probable therapeutic approaches of flavonoids aimed at averting or slowing the progression of the AD pathogenesis.

Links

PMC Free PDF

Authors+Show Affiliations

Uddin MS
Department of Pharmacy, Southeast University, Dhaka 1213, Bangladesh. Pharmakon Neuroscience Research Network, Dhaka 1207, Bangladesh.
Kabir MT
Department of Pharmacy, BRAC University, Dhaka 1212, Bangladesh.
Niaz K
Department of Pharmacology and Toxicology, Faculty of Bio-Sciences, Cholistan University of Veterinary and Animal Sciences (CUVAS), Bahawalpur 63100, Pakistan.
Jeandet P
Research Unit, Induced Resistance and Plant Bioprotection, EA 4707, SFR Condorcet FR CNRS 3417, Faculty of Sciences, University of Reims Champagne-Ardenne, PO Box 1039, 51687 Reims Cedex 2, France.
Clément C
Research Unit, Induced Resistance and Plant Bioprotection, EA 4707, SFR Condorcet FR CNRS 3417, Faculty of Sciences, University of Reims Champagne-Ardenne, PO Box 1039, 51687 Reims Cedex 2, France.
Mathew B
Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad, Kerala 678557, India.
Rauf A
Department of Chemistry, University of Swabi, Anbar, 23561, Khyber Pakhtunkhwa, Pakistan.
Rengasamy KRR
Department of Bioresources and Food Sciences, Konkuk University, Seoul 05029, Korea.
Sobarzo-Sánchez E
Instituto de Investigación e Innovación en Salud, Facultad de Ciencias de la Salud, Universidad Central de Chile, Santiago 8330507, Chile. Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Ashraf GM
King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia. Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Aleya L
Chrono-Environnement Laboratory, UMR CNRS 6249, Bourgogne Franche-Comté University, F-25030 Besançon, France.

MeSH

Alzheimer DiseaseAmyloid beta-PeptidesAutophagyCholinesterasesCognitionCognitive DysfunctionDisease ProgressionFlavonoidsGene Expression RegulationHumansNeuroprotective AgentsNootropic AgentsPhosphorylationPlaque, AmyloidProtein AggregatesSignal Transductiontau Proteins

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32168835

Citation

Uddin, Md Sahab, et al. "Molecular Insight Into the Therapeutic Promise of Flavonoids Against Alzheimer's Disease." Molecules (Basel, Switzerland), vol. 25, no. 6, 2020.
Uddin MS, Kabir MT, Niaz K, et al. Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease. Molecules. 2020;25(6).
Uddin, M. S., Kabir, M. T., Niaz, K., Jeandet, P., Clément, C., Mathew, B., Rauf, A., Rengasamy, K. R. R., Sobarzo-Sánchez, E., Ashraf, G. M., & Aleya, L. (2020). Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease. Molecules (Basel, Switzerland), 25(6). https://doi.org/10.3390/molecules25061267
Uddin MS, et al. Molecular Insight Into the Therapeutic Promise of Flavonoids Against Alzheimer's Disease. Molecules. 2020 Mar 11;25(6) PubMed PMID: 32168835.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease. AU - Uddin,Md Sahab, AU - Kabir,Md Tanvir, AU - Niaz,Kamal, AU - Jeandet,Philippe, AU - Clément,Christophe, AU - Mathew,Bijo, AU - Rauf,Abdur, AU - Rengasamy,Kannan R R, AU - Sobarzo-Sánchez,Eduardo, AU - Ashraf,Ghulam Md, AU - Aleya,Lotfi, Y1 - 2020/03/11/ PY - 2020/02/06/received PY - 2020/03/05/revised PY - 2020/03/10/accepted PY - 2020/3/15/entrez PY - 2020/3/15/pubmed PY - 2020/12/22/medline KW - Alzheimer’s disease KW - PI3K/Akt signaling, MAPK signaling, mTOR KW - amyloid plaque KW - flavonoids KW - neurofibrillary tangles JF - Molecules (Basel, Switzerland) JO - Molecules VL - 25 IS - 6 N2 - Alzheimer's disease (AD) is one of the utmost chronic neurodegenerative disorders, which is characterized from a neuropathological point of view by the aggregates of amyloid beta (Aβ) peptides that are deposited as senile plaques and tau proteins which form neurofibrillary tangles (NFTs). Even though advancement has been observed in order to understand AD pathogenesis, currently available therapeutic methods can only deliver modest symptomatic relief. Interestingly, naturally occurring dietary flavonoids have gained substantial attention due to their antioxidative, anti-inflammatory, and anti-amyloidogenic properties as alternative candidates for AD therapy. Experimental proof provides support to the idea that some flavonoids might protect AD by interfering with the production and aggregation of Aβ peptides and/or decreasing the aggregation of tau. Flavonoids have the ability to promote clearance of Aβ peptides and inhibit tau phosphorylation by the mTOR/autophagy signaling pathway. Moreover, due to their cholinesterase inhibitory potential, flavonoids can represent promising symptomatic anti-Alzheimer agents. Several processes have been suggested for the aptitude of flavonoids to slow down the advancement or to avert the onset of Alzheimer's pathogenesis. To enhance cognitive performance and to prevent the onset and progress of AD, the interaction of flavonoids with various signaling pathways is proposed to exert their therapeutic potential. Therefore, this review elaborates on the probable therapeutic approaches of flavonoids aimed at averting or slowing the progression of the AD pathogenesis. SN - 1420-3049 UR - https://www.unboundmedicine.com/medline/citation/32168835/Molecular_Insight_into_the_Therapeutic_Promise_of_Flavonoids_against_Alzheimer's_Disease_ DB - PRIME DP - Unbound Medicine ER -